StreetInsider.com News Articles

Dermata gets Australian patent acceptance for dermal filler delivery system

Thu, 02 Apr 2026 08:33:11 -0400

Dermata Therapeutics Inc. (NASDAQ: DRMA) received notice of acceptance from the Australian Patent Office for its patent application covering topical dermal filler delivery using its Bioneedle Delivery System, the company announced April 2.

The patent application, titled "Compositions for the treatment of conditions by dermal fillers" (Australian Patent Application No. 2020315876), addresses topical delivery of dermal fillers rather than traditional injectable methods. The patent will be automatically issued three months after acceptance unless a third party files an opposition.

This represents Dermata's first patent covering the use of its Bioneedle Delivery System with dermal fillers, if issued. The company already holds allowed

Dermata gets Australian patent acceptance for dermal filler delivery system

Thu, 02 Apr 2026 08:33:11 -0400

This represents Dermata's first patent covering the use of its Bioneedle Delivery System with dermal fillers, if issued. The company already holds allowed

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Thu, 02 Apr 2026 08:30:00 -0400

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -

- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -

SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Thu, 02 Apr 2026 08:30:00 -0400

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -

- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Thu, 02 Apr 2026 08:30:00 -0400

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -

- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Thu, 02 Apr 2026 08:30:00 -0400

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -

- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -

Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch

Tue, 10 Mar 2026 08:32:23 -0400

Dermata Therapeutics (NASDAQ: DRMA) announced the appointment of Kyra Peckaitis as Vice President, Marketing, effective March 9. Peckaitis will lead the marketing strategy for Dermata's Tome Skincare brand, which plans to launch its first commercial products in mid-2026.

Peckaitis brings experience from wellness and personal care consumer brands. She previously served as Associate Director, Brand Marketing for Coterie, a direct-to-consumer baby care brand, and worked on global brand teams for HubSpot and integrated marketing at Sweetgreen. She holds a B.S. in Marketing from the University of Maryland's Robert H. Smith School of Business.

"As we get ready to launch our first commercial

Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch

Tue, 10 Mar 2026 08:32:23 -0400

"As we get ready to launch our first commercial

Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch

Tue, 10 Mar 2026 08:32:23 -0400

"As we get ready to launch our first commercial

Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch

Tue, 10 Mar 2026 08:32:23 -0400

"As we get ready to launch our first commercial

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Tue, 10 Mar 2026 08:30:00 -0400

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA)(Nasdaq:DRMAW), a science-driven leader in dermatologic solutions, today announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata's new brand launch, Tome Skincare. Ms. Peckaitis will oversee the marketing strategy, brand development, and consumer engagement initiatives as Tome gets ready to bring its first commercial products to market in

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Tue, 10 Mar 2026 08:30:00 -0400

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Tue, 10 Mar 2026 08:30:00 -0400

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Tue, 10 Mar 2026 08:30:00 -0400

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -

Dermata Opens a New Chapter with the Release of Tome Skincare

Thu, 05 Mar 2026 09:00:00 -0400

-The oldest new thing in skincare -

- Dermata expects to launch its first product in the middle of 2026 -

SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today proudly announces the branding of its latest innovation in skincare: Tome, which aims to introduce "skintech at home". The Company's Tome skincare line will bring intentionally developed skincare that delivers a high level of efficacy by addressing the root causes of skin diseases and conditions. Tome is

Dermata Opens a New Chapter with the Release of Tome Skincare

Thu, 05 Mar 2026 09:00:00 -0400

-The oldest new thing in skincare -

- Dermata expects to launch its first product in the middle of 2026 -

Dermata Opens a New Chapter with the Release of Tome Skincare

Thu, 05 Mar 2026 09:00:00 -0400

-The oldest new thing in skincare -

- Dermata expects to launch its first product in the middle of 2026 -

Dermata Opens a New Chapter with the Release of Tome Skincare

Thu, 05 Mar 2026 09:00:00 -0400

-The oldest new thing in skincare -

- Dermata expects to launch its first product in the middle of 2026 -

Dermata receives Australian patent for Spongilla acne treatment technology

Tue, 20 Jan 2026 08:05:30 -0400

Dermata Therapeutics Inc. (NASDAQ: DRMA) announced the Australian Patent Office granted its patent application for Spongilla technology combination as a method for treating acne. The patent, titled "Compositions and methods for the treatment of skin conditions" (Australian Patent No. 2019419387), follows a previously issued U.S. patent covering the same technology.

The company expects to launch a once-weekly, over-the-counter acne treatment system incorporating its Spongilla technology in mid-2026, initially in the United States. The system combines an active ingredient from the OTC monograph with the company's proprietary technology.

"We are excited to receive this granted patent from the Australian patent office as we

Dermata receives Australian patent for Spongilla acne treatment technology

Tue, 20 Jan 2026 08:05:30 -0400

"We are excited to receive this granted patent from the Australian patent office as we

Dermata receives Australian patent for Spongilla acne treatment technology

Tue, 20 Jan 2026 08:05:30 -0400

"We are excited to receive this granted patent from the Australian patent office as we

Dermata receives Australian patent for Spongilla acne treatment technology

Tue, 20 Jan 2026 08:05:30 -0400

"We are excited to receive this granted patent from the Australian patent office as we

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Tue, 20 Jan 2026 08:05:00 -0400

This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne
Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.
Over 3.3 million people are diagnosed with acne in Australia

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 20, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has granted its patent application for

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Tue, 20 Jan 2026 08:05:00 -0400

This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne
Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.
Over 3.3 million people are diagnosed with acne in Australia

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Tue, 20 Jan 2026 08:05:00 -0400

This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne
Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.
Over 3.3 million people are diagnosed with acne in Australia